KIKoki Ise

Koki Ise

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Koki Ise has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Reduced Gene Module for Spatial Transcriptomics Recapitulates Single‐Cell Molecular Classifications of Glioblastoma

    by Koki Ise, Zen‐Ichi Tanei, Takeru Kuwabara, Jintao He, Yoshitaka Oda, Lei Wang, Hirokazu Sugino, Ken‐Ichi Sato, Masumi Tsuda, Shinya Tanaka

    Glioblastoma, IDH ‐wildtype, is the most common and malignant adult‐type diffuse glioma. It is characterized by extensive heterogeneity and poor prognosis. Recent single‐cell RNA‐sequencing studies have revealed distinct transcriptional programs that define cellular states such as astrocyte‐like, mesenchymal‐like, neural‐progenitor‐cell‐like, and oligodendrocyte‐progenitor‐cell‐like. However, their spatial context remains unclear because of the limitations of single‐cell and spot‐based spatial transcriptomics. In the present study, we applied a single‐cell molecular classification of glioblastoma to a spatial transcriptomic analysis using the Xenium in situ platform. A custom gene panel comprising 366 genes, including 100 additional genes beyond the predesigned central nervous system panel, was designed to enable high‐resolution, cell‐level analysis. We constructed reduced modules derived from the Neftel et al. classification and validated their reproducibility across public single‐cell datasets, achieving approximately 80% concordance with the original modules. In three cases of glioblastoma, IDH ‐wildtype, spatial transcriptomic profiling revealed regional variations in transcriptional states; cellular tumor regions, regions of pseudopalisading necrosis were significantly enriched in reduced neural‐progenitor‐like‐cells subtype 1, and reduced mesenchymal‐like‐cells subtype 2, respectively. Our data indicate that the novel reduced module provides a framework for investigating single‐cell molecular states within a tissue context in glioblastoma.

  • Urothelial Carcinoma With Loss of SMARCA4 Expression With the Site of Origin Identified by Detailed Autopsy Investigation

    by Takeru Kishinami, Yoshitaka Oda, Zen‐Ichi Tanei, Takahiro Osawa, Riku Manabe, Ryoko Watanabe, Yuki Hirosato, Yuki Uchida, Akira Nishibe, Kazuhiro Ujihashi, et al.

  • Open Access

    Intraindividual histopathological comparison of embolized and nonembolized territories in recurrent chronic subdural hematoma after middle meningeal artery embolization: illustrative case

    by Shunichiro Saiki, Yasuyuki Tatsuta, Koki Ise, Masahiro Okuma, Toshiaki Osato, Zen-Ichi Tanei, Hirohiko Nakamura

    BACKGROUND: Middle meningeal artery (MMA) embolization is a minimally invasive treatment for chronic subdural hematoma (CSDH) that reduces recurrence by interrupting the vascular supply to the outer membrane; however, the mechanisms underlying recurrence remain incompletely understood. OBSERVATIONS: An 80-year-old man with recurrent CSDH after burr hole evacuation underwent MMA embolization. The anterior convexity branch, identified as the principal feeder, was successfully embolized using 20% n -butyl-2-cyanoacrylate (NBCA). The posterior convexity branch did not demonstrate membrane staining, and embolization was therefore concluded. Despite initial improvement, recurrence required craniotomy. Intraoperative indocyanine green angiography demonstrated no flow in the embolized territory, whereas preserved and newly developed blood flow was observed in the nonembolized territory. Histopathological examination revealed preserved vascular structures with abundant neovascularization in the nonembolized region. In contrast, the embolized region showed reticular NBCA casts within MMA branches and penetrating vessels, accompanied by endothelial desquamation, medial thinning, and mild lymphocytic infiltration. NBCA fragments were also identified within the outer membrane, associated with foreign body reactions. LESSONS: Recurrence may result from collateral flow from nonembolized MMA branches, even after technically successful embolization. Histological findings support NBCA penetration into the outer membrane and highlight the importance of tailored and potentially more comprehensive embolization strategies. https://thejns.org/doi/10.3171/CASE26423

  • Open Access

    Myofibre Density Reveals a Critical Threshold Around Age 6 in Steroid‐Naïve Duchenne Muscular Dystrophy: A Retrospective Observational Study

    by Tetsuhiro Yamakado, Yuka Ishikawa, Koki Ise, Lei Wang, Yoshitaka Oda, Masumi Tsuda, Taichi Kimura, Masayoshi Nagao, Manabu Ito, Shinya Tanaka, et al.

    Aims: In Duchenne muscular dystrophy (DMD), robust histological markers for assessing early disease progression remain elusive. We defined myofibre density ( MFD ) as the count of myofibres per square millimetre, which, in our preliminary survey of DMD muscle biopsies, steeply declined with age (Spearman's ρ : −0.85). We aimed to characterise age‐dependent MFD dynamics in early‐stage DMD. Methods: We retrospectively assessed 46 archival muscle‐biopsy slides (steroid‐naïve; collected > 40 years ago) using semi‐quantitative image analysis with digital restoration. MFD and classical histological variables were quantified. Age– MFD dynamics were modelled with segmented regression and validated using weakly informative Bayesian modelling. The primary measure was the MFD age‐breakpoint. Secondary measures included breakpoint‐detection power, age‐predictive MFD cut‐offs and behaviour of conventional variables across breakpoint‐defined age bands. Results: After quality and age‐distribution screening, 35 slides (age 1–11 years) were analysed. Segmented regression identified a breakpoint at 6.25 years (95% confidence interval [CI]: 5.08–7.42); after which MFD plateaued at lower levels. Bayesian posterior estimate was 6.37 years (95% credible interval: 5.24–7.66). A 10,000‐run Monte Carlo simulation ( n = 35) showed approximately 80% power to recapture the breakpoint within ±1.25 years. MFD cut‐offs > 596 and < 426 fibres/mm 2 corresponded to 80% and 20% probabilities of age < 6.25 years. Between the early (< 5 years) and late (≥ 7.5 years) age bands defined by the breakpoint–CI limits, myofibre‐size parameters, myofibre area and fat replacement shifted significantly. Conclusions: MFD , a simple metric, reveals a previously unrecognised phase of rapid myofibre loss lasting up to around age 6 in early‐stage DMD.

  • Open Access

    Induction of meningioma stem signature via hydrogel reprogramming and application of meningioma stem cell marker CXCR4 to pathological diagnosis and treatment

    by Yoshitaka Oda, Masumi Tsuda, Lei Wang, Jun Suzuka, Sayaka Yuzawa, Kouki Ise, Umma Habiba, Jintao He, Satoshi Tanikawa, Hirokazu Sugino, et al.

    Backgrounds: Meningioma accounts for about 40% of brain tumors, but there was no effective treatment for recurrent or inoperable cases. We have previously found that when cancer cells are cultured on certain hydrogels, cancer stem cells are efficiently induced in various cancer types and we named this process as hydrogel activated reprogramming (HARP) phenomenon. In this study, we aimed to identify a key molecule that induced meningioma stem cells via hydrogels. Methods: Meningioma cells cultured on hydrogels were analyzed for expression of regular stem cell markers and their tumor genericity. Microarray analysis was performed to identify meningioma stem cell specific markers and to examine the application of such marker molecules as a therapeutic targets or pathological diagnosis for grading. Results: Regular stem cell markers such as Nanog , and Oct3/4 were induced by culturing meningioma cells on hydrogels, and comprehensive gene expression analysis identified molecules involved in cancer stem cell activity. Among them, CXCR4 was selected as a therapeutic target molecule. Stimulation of CXCR4 via CXCL12 led to an increase in stem cell markers. In human meningioma pathological specimens and cultured cell lines, there was a correlation between CXCR4 expression levels and NF2 mutations and/or deletions. CXCR4 immunohistochemistry also detected along with the brain invasion. Thus, CXCR4 immunohistochemistry may be useful to suggest typical CNS WHO grade 1 meningioma, that do not require molecular analysis. Conclusions: We have defined meningioma stem cell signature via HARP phenomenon and identified CXCR4 with biological significance as being diagnostic target. Key Points: We induce meningioma stem signature via Hydrogel activated reprogramming (HARP) phenomena. We identified CXCR4 as a candidate molecule as stemness marker and therapeutic target. Translational research using pathological specimens reveal CXCR4 immunohistochemistry has been shown to play an auxiliary role in the diagnosis of meningiomas. Importance of the Study: In addition to morphology, immunohistochemistry and gene alteration are being adopted as diagnostic criteria for CNS tumors. From CNS5 onwards, epigenetic changes such as methylation analysis are being adopted as diagnostic criteria. We induced epigenetic changes in meningioma cells and induced cancer stemness, and this technique will be of great importance in the research and diagnosis of meningioma. In addition, microarray analysis was used to select CXCR4 from the molecules that increased simultaneously during stem cell induction on the three hydrogels, and further analysis revealed that CXCR4 immunostaining may indicate the distribution of meningioma stem cells, also making it useful for diagnosis. This report will contribute to the advancement of meningioma research and diagnosis by conducting basic research and using histopathological specimens.